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Abbreviations
ApoA-I apolipoprotein A-I
FAV forearm tissue volume
FBF forearm blood flow
L-NMMA N
G monomethyl-L-arginine
M/C ratio of flow in infused measurement
and non-infused control arm
NO nitric oxide
rHDL reconstituted HDL
SNP sodium nitroprusside
To the Editor: HDL-cholesterol is inversely correlated
with cardiovascular events in all major epidemiological
studies [1]. HDL-increasing strategies have demonstrated that
HDL-cholesterol increase is associated with decreased car-
diovascular risk in high-risk individuals such as patients with
type 2 diabetes [2]. Endothelial dysfunction, a hallmark of
type 2 diabetes patients, has been shown to predict future
cardiovascular events [3]. Therefore, we investigated the
effect of reconstituted HDL (rHDL) on endothelial function
measured both acutely (4 h after infusion) and 7 days after
infusion in type 2 diabetes patients. Control volunteers were
measured only at baseline and 4 h after infusion.
Seven non-smoking patients with type 2 diabetes (four
men and three women, BMI 24.4±1.6 kg/m
2) and seven
matched control volunteers (four men and three women,
BMI 22.9±1.8 kg/m
2) were enrolled. Inclusion criteria for
type 2 diabetes patients were: (1) fasting glucose
>7.0 mmol/l; (2) no insulin therapy; and (3) triacylglycerol
and LDL-cholesterol levels <2.0 and <3.5 mmol/l, respec-
tively. Matched control individuals were volunteers who
were recruited via advertisements. The presence of macro-
vascular disease (ECG abnormalities, abnormal ankle–
brachial index or a history of cardiovascular events) served
as exclusion criteria. Female participants were postmeno-
pausal and not using hormone replacement therapy. The
study protocol was performed at least 4 weeks after
discontinuation of vasoactive medication, including ACE
inhibitors, angiotensin receptor blockers and non-steroidal
anti-inflammatory drugs. None of the patients or control
volunteers used lipid-lowering medication. The Internal
Review Board of the Academic Medical Center approved
the study and all individuals gave written informed
consent.
Vascular function was assessed using venous occlusion
strain-gauge plethysmography (EC-4; Hokanson, Washington,
DC, USA) [4]. Forearm blood flow (FBF), expressed as
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−1 100 ml
−1 forearm tissue volume (FAV), was
measured simultaneously in both arms. FBF responses to
cumulative doses of the endothelium-dependent vasodilator
serotonin (Sigma, Poole, UK; 0.6, 1.8 and 6 ng 100 ml
−1
FAV min
−1), the endothelium-independent vasodilator so-
dium nitroprusside (SNP; Spruyt Hillen, IJsselstein, the
Netherlands; 6, 60, 180 and 600 ng 100 ml
−1 FAV min
−1),
and the competitive inhibitor of endothelial nitric oxide
(NO) synthase N
G-monomethyl-L-arginine (L-NMMA;
Kordia, Leiden, the Netherlands; 50, 100, 200 and 400 μg
100 ml
−1 FAV min
−1) were measured. Agents were
administered intra-arterially for 6, 4 and 8 min at each
dose, respectively. Average FBF values of the measurement
(cannulated) and control arm were obtained from the last
six measurements of each measurement period. The three
different infusion blocks proceeded after a 15 min rest
period or until FBF had returned to baseline. The ratio of
flow in the infused measurement (M) and non-infused
control (C) arm was calculated for each recording (M/C
ratio). The average value of the M/C ratio was calculated
from these four to six M/C ratios, thus providing an internal
control by excluding systemic factors from influencing the
results [5]. Subsequently, a venous catheter was inserted in
the contralateral arm for administration of rHDL (CSL-111;
CSL Bioplasma, Parkville, VIC, Australia) at a dose of
80 mg/kg body weight over a period of 4 h. Subsequently,
the infusion blocks were repeated. Blood samples were
drawn from the individuals after a 12 h overnight fast, and
at 4 h and 7 days after rHDL infusion. Descriptive statistics
between the two groups were compared by two-tailed
independent Student’s t tests or non-parametric tests,
depending on skewedness of the data. Analysis of measure-
ments for individuals between baseline and 4 h as well as
baseline and 7 days after rHDL infusion was performed by
two-way ANOVA for repeated measures with Bonferroni
correction.
Infusion of rHDL was well tolerated and no adverse
events were recorded. Characteristics of type 2 diabetes
patients and control volunteers during each measurement
are listed in Table 1. Baseline FBFs were not significantly
different between type 2 diabetes patients and control
individuals (Table 1). Intra-arterial infusion of serotonin
increased FBF in a dose-dependent manner in both groups
(see Fig. 1a). At baseline, the FBF response to serotonin
was attenuated in type 2 diabetes compared with control
volunteers (M/C ratio in type 2 diabetes: 1.5±0.2 vs
controls: 2.5±0.3; p<0.05). Four hours after rHDL infusion
in type 2 diabetes, FBF response to serotonin increased
significantly (M/C ratio to 1.9±0.2; p<0.05 compared with
baseline). rHDL infusion had no significant effect on
serotonin-induced vasodilation in control volunteers. In
type 2 diabetes, 7 days after rHDL infusion serotonin
responses had returned to baseline values (7 days, 1.5±0.2).
At baseline, the maximal vasoconstrictor response to L-
NMMA was blunted in type 2 diabetes compared with
control volunteers (M/C ratio controls 0.6±0.1 vs type 2
diabetes 1.0±0.2; p<0.05, Fig. 1b). After rHDL infusion,
the L-NMMA response improved in type 2 diabetes
Table 1 Clinical characteristics of type 2 diabetes patients and control volunteers
Type 2 diabetes patients (n=7) Control volunteers (n=7)
Baseline 4 h 7 days Baseline 4 h
Waist circumference (cm) 101±5 90±6
†
Metabolic syndrome 6/7 0/7
Systolic BP (mmHg) 148±12 146±11 143±7 135±16 138±12
Diastolic BP (mmHg) 78±13 79±13 82±8 83±9 85±8
Heart rate (beats per min) 65±9 67±9 66±12 61±9 64±8
Total cholesterol (mmol/l) 5.6±0.4 6.5±1.4 5.4±1.3 5.3±0.4 6.7±1.3
LDL-cholesterol (mmol/l) 2.9±0.6 3.3±1.1 3.1±1.0 3.0±0.7 3.9±1.2
HDL-cholesterol (mmol/l) 1.1±0.2 2.7±0.7* 1.6±0.6 1.2±0.3 2.5±0.4*
ApoA-I (g/l) 1.2±0.1 2.8±0.4* 1.5±0.3 1.2±0.2 2.7±0.4*
Triacylglycerol (mmol/l) 1.5±0.4 1.6±0.6 1.6±0.5 0.8±0.3
† 1.8±1.3*
Glucose (mmol/l) 8.3±1.2 6.8±1.7 7.3±1.3 5.2±0.4
† 4.9±0.2
hsCRP (mg/l) 3.5±1.6 4.4±1.7 3.6±0.8 1.0±0.9
† 1.8±1.1
ASAT (U/l) 22.5±2.5 20.4±4.0 22.4±4.3 20.2±1.8 21.4±2.7
ALAT (U/l) 31.2±6.9 26.0±9.7 27.8±8.7 14.9±1.7
† 15.6±3.2
Basal FBF (ml 100 ml
−1 FAV min
−1) 4.1±2.0 3.7±0.8 3.9±1.3 2.6±0.9 2.8±0.7
Values are means±SD
*p<0.05 compared with baseline within one group;
†p<0.05 between type 2 diabetes and control volunteers ALT, alanine aminotransferase;
ASAT, aspartate aminotransferase; hsCRP, high-sensitivity C-reactive protein
1082 Diabetologia (2008) 51:1081–1084compared with baseline (0.7±0.1; p<0.05). Although not
significant, 7 days after rHDL infusion there still was a
tendency towards improvement in type 2 diabetes (M/C
ratio 0.8±0.1 compared with baseline). rHDL infusion had
no effect on L-NMMA response in control individuals.
Finally, SNP responses were lower in type 2 diabetes vs
control individuals at baseline (M/C ratio in type 2 diabetes,
3.0±0.6 vs control individuals, 5.3±0.7; p<0.05, Fig. 1c)
and rHDL infusion had no effect on SNP responses.
In conclusion, the present study confirms that basal and
stimulated NO bio-availability is reduced in type 2 diabetes
patients compared with control volunteers. Besides hyper-
glycaemia-induced reactive oxygen radical formation, other
components of type 2 diabetes-associated dyslipidaemia
such as small dense LDL are known to influence
endothelial function in type 2 diabetes [3, 6]. Moreover,
the high prevalence of metabolic syndrome in our patients
is in line with previously published data [7]. rHDL resulted
in a significant improvement of endothelial function within
several hours in type 2 diabetes patients. More importantly,
there was still a tendency towards improved NO availability
7 days after infusion, at a time when apolipoprotein A-I
(ApoA-I) increase had largely disappeared. Acute HDL-
increasing strategies are actively being pursued for further
reducing cardiovascular burden [8], and thus far the lack of
selective and potent HDL-increasing drugs has limited the
success of the HDL-cholesterol increase concept. Our
reported beneficial effects of ApoA-I infusion may lend
further support to the development of ApoA-I-increasing
strategies, also for patients with type 2 diabetes.
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